The problem
Coverage is reported as a number long after the doctors that mattered were missed.
Coverage intelligence flags the doctors going uncovered while there is still a cycle left to fix it.
What is a doctor coverage gap?
A high-value or planned doctor who is not being seen at the intended frequency, often invisible until the cycle is over and the number is reported.
Why is coverage usually found out too late?
It is reviewed monthly as an aggregate. By the time the percentage is read, the specific A-class doctors that drove it have already been missed.
What is the better signal?
Not a coverage percentage at month end, but which named doctors are slipping now, ranked by value, with cycle still remaining.
Is low coverage always the rep's fault?
No. It can be routing, territory design or plan realism. The point is to surface the cause early enough to choose the right fix.
Coverage is one of the most reported numbers in pharma field operations and one of the least actionable, because it usually arrives as a percentage after the cycle that produced it has closed. By then the specific doctors that mattered were already missed.
Aggregate too late beats specific too early, every time it is reversed
A month-end coverage figure is a post-mortem. The useful version is the opposite: which named, high-value doctors are slipping right now, ranked, with cycle remaining. That is a signal a manager can act on, not a score they have to explain in the review.
Coverage is not call count
Activity and coverage are different questions. A rep can be busy and still miss the doctors who move the territory. Treating call count as coverage hides the gap that matters.
The fix depends on the cause
A coverage gap can be a rep behaviour issue, a routing problem, an unrealistic plan, or a territory design flaw. Surfacing it early is what makes it possible to choose the right correction instead of guessing after the fact.
The PharmaOS point of view
The next advantage in pharma is decision intelligence, not a larger field force or more dashboards.
The first generation of Indian pharma built access. The second built scale. The next will run on commercial intelligence: every rep, manager and brand head acting on the real reason, in time to change the outcome.
Related companies
Continue
See the operating intelligence layer.
A 20-minute private walkthrough on a slice of your own commercial data. Nothing migrated, nothing stored.
FAQ
It changes when the report is useful, from a post-mortem to an in-cycle prompt.
No. Call count is activity. Coverage is whether the right doctors were actually reached.
Coverage should be a forward signal a manager can act on, not a backward score they explain.